nach oben

Current Rheumatology Reports

Erschienen in:

01.12.2013 | SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Top 10 Recent Developments in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

verfasst von: Anisha B. Dua, Zahi Touma, Sergio Toloza, Meenakshi Jolly

Erschienen in: Current Rheumatology Reports | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that has major implications for health-related quality of life (HRQoL). Improvements in the monitoring and management of SLE improves survival; however, improvement of HRQoL remains of paramount importance among these patients. Measurement of HRQoL has been recommended in clinical practice and research including drug development and testing in clinical trials. Both generic and disease specific instruments have been developed to ascertain HRQoL. In an increasingly global collaborative environment, the importance of assessing HRQoL across nations, acknowledgment of their confounders, and limitations of used instruments are critical. Here, we review selected major developments in the past 5 years highlighting: the importance of measuring HRQoL in SLE patients, the benefits and limitations of instruments that exist, and their application in research settings.

Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59–65.PubMedCrossRef

Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;35(11):2152–8.PubMedCrossRef

Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol. 2005;32(9):1706–8.PubMed

Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol. 1999;26(2):504–7.PubMed

FDA Guidance on Patient Reported Outcomes. “http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282pdf” [Internet]. 2010.

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus. 2000;9(5):322–7.PubMedCrossRef

Alarcon GS, McGwin Jr G, Uribe A, Friedman AW, Roseman JM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA).XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum. 2004;51(3):465–74.PubMedCrossRef

McElhone K, Abbott J, Gray J, Williams A, Teh LS. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus. 2010;14:1640–7.CrossRef

Jolly M, Utset TO. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus. 2004;13(12):924–6.PubMedCrossRef

10.

Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009;68(2):196–200. Erratum appears in Ann Rheum Dis. 2011 Aug;70(8):1519.PubMedCrossRef

11.

Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(3):568–73.PubMedCrossRef

12.

Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum. 2009;61(2):240–6.PubMedCrossRef

13.

Stamm TA, Bauernfeind B, Coenen M, Feierl E, Mathis M, Stucki G, et al. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum. 2007;57(7):1287–95.PubMedCrossRef

14.

• Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semi Arthritis Rheum. 2012;42(1):56–65. This article describes the development, reliabililty and validity of LupusPRO; a disease-targeted patient-reported health outcome tool. CrossRef

15.

Burckhardt CS, Archenholtz B, Bjelle A. Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. J Rheumatol. 1993;20(6):977–81.PubMed

16.

Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16.PubMedCrossRef

17.

Kuriya BGD, Ibañez D, Urowitz MB. Quality of Life over time in patients with systemic Lupus Erythematosus. Arthritis Rheum. 2008;59(2):181–5.PubMedCrossRef

18.

Harrison MJ, Ahmad Y, Haque S, Dale N, Teh LS, Snowden N, et al. Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus. J Rheumatol. 2012;39(4):735–42.PubMedCrossRef

19.

Yazdany J. Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL). Arthritis Care Res. 2011;63 Suppl 11:S413–9. Review.CrossRef

20.

• Castelino M, Abbott J, McElhone K, LS T. Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature. Rheumatology (Oxford). 2013;52(4):684–96. This article compares the psychometric properties of different HRQoL questionnaires.

21.

Ow YLM, Thumboo J, Cella D, Cheung YB, Yong Fong K, Wee HL. Domains of health-related quality of life important and relevant to multiethnic English-speaking Asian systemic lupus erythematosus patients: a focus group study. Arthritis Care Res. 2011;63(6):899–908.CrossRef

22.

Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology. 2005;44(10):1267–76.PubMedCrossRef

23.

Body Image: A handbook of theory, Research, & Clinical Practice. NY: Guilford Press; 2002, 2002.

24.

Jolly M, Pickard AS, Mikolaitis RA, et al. Body image in patients with systemic Lupus Erythematosus. Int J Behav Med. 2012;19(2):157–64.PubMedCrossRef

25.

Toloza SM, Jolly M, Alarcon GS. Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues. Curr Rheumatol Rep. 2010;12(4):237–49. Review.PubMedCrossRef

26.

Jolly M, Cornejo J, Mikolaitis RA, JA B. LupusPRO and responsiveness to changes in health status and disease activity over time. Arthritis Rheum. 2011;63(10s):S898-S.

27.

Jolly M, Kosinski M, SM T, al e. Equivalence of various language versions of Lupus Specific Patient Reported Outcome Measure: LupusPRO. Arthritis & Rheum. 2012;4(10):S607-S.

28.

Jolly M, Block JA, RA M, al e. Spanish LupusPRO: cross cultural validation study for lupus. Arthritis & Rheumatism. 2011;63(10s):S725.

29.

Salvador M, Tananguan RM, Jolly M, Navarra SV. Validation of the Filipino version of LupusPro(R) questionnaire among Filipino patients with systemic lupus erythematosus: APLAR-0471. Int J Rheum Dis. 2013;16(Supplement 1):82. Abstract.

30.

Navarra SV, Tanangunan RM, Mikolaitis-Preuss RA, Kosinski M, Block JA, Jolly M. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. Lupus. 2013;22(3):262–7.PubMedCrossRef

31.

Bourre-Tessier J, Clarke AE, Mikolaitis-Preuss RA, Kosinski M, Bernatsky S, Block JA, et al. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic Lupus Erythematosus in Canada. J Rheumatol. 2013;40(8):1327–33.PubMedCrossRef

32.

Bourré-Tessier J, Clarke AE, Mikolaitis-Preuss RA, Kosinski M, Block JA, M J. Validation of French version of LupusPRO among Canadian Lupus patients. Arthritis & Rheumatism. 2012;64(10s):S947-S.

33.

Kaya A, Goker B, Cura ES, Tezcan ME, Tufan A, al e. Turkish lupusPRO: cross-cultural validation study for lupus. Clin Rheumatol 2013 Aug 11[Epub ahead of print]. 2013.

34.

Jolly M, Kosinski M, Garris CP, et al. Development of the Lupus Impact Tracker: a tool for patients and physicians to assess and monitor the impact of systemic lupus erythematosus. Value Health. 2011;14(3):A 65–A6. Abstract.

35.

Jolly M, Kosinski M, Garris CP, Ogelsby A. Validation of the Lupus Impact Tracker (LIT), a patient reported outcome tool, in a prospective multicenter longitudinal study of systemic lupus erythematosus patients. Value Health. 2012;15(7):A 515.CrossRef

36.

Jolly M, Kosinski M, Garris CP. Validation of the Lupus Tracker. Value in Health. Value Health. 2011;14(3):A 65.

37.

Jolly M, Pickard AS, Sequeira W, Wallace DJ, Solem CT, et al. A brief assessment tool for body image in systemic lupus erythematosus. Body Image. 2012;9(2):279–84.PubMedCrossRef

38.

McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57(6):972–9.PubMedCrossRef

39.

Moorthy LN, Peterson MG, Baratelli MJ, al e. Preliminary cross-cultural adaptation of a new pediatric health-related quality of life scale in children with systemic lupus erythematosus: an international effort. Lupus. 2010. p. 83–8.

40.

• Kasitanon N, Wangkaew S, Puntana S, Sukitawut W, Leong KP, TTSHLS Group, et al. The reliability, validity and responsiveness of the Thai version of Systemic Lupus Erythematosus quality of life (SLEQOL-TH) instrument. Lupus. 2013;22(3):289–96. This article highlights the psychometric properties of the Thai version of SLEQOL-TH questionnaire. PubMedCrossRef

41.

Kong KO, Ho HJ, Howe HS, Thong BY, Lian TY, Chng HH, et al. Cross-cultural adaptation of the systemic Lupus Erythematosus quality of life questionnaire into Chinese. Arthritis Rheum. 2007;57(6):980–5.PubMedCrossRef

42.

Freire EA, Bruscato A, Leite DR, Sousa TT, Ciconelli RM. Translation into Brazilian Portuguese, cultural adaptation and validatation of the systemic lupus erythematosus quality of life questionnaire (SLEQOL). Acta Reumatologica Portuguesa. 2010;35(3):334–9.PubMed

43.

Jolly M, Pickard AS, Wilke C, Mikolaitis RA, Teh LS, McElhone K, et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis. 2009;69:29–33.CrossRef

44.

Gonzalez-Rodriguez V, Peralta-Ramirez MI, Navarrete-Navarrete N, Callejas-Rubio JL, Santos Ruiz AM, Khamashta M. Adaptation and validation of the Spanish version of a disease-specific quality of life measure in patients with systemic lupus erythematosus: the Lupus quality of life. Med Clin. 2010;134(1):13–6. Spanish.CrossRef

45.

Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, et al. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology. 2012;51(10):1906–15.PubMedCrossRef

46.

Jolly M, Toloza S, Block J, Mikolaitis R, Kosinski M, Wallace D, et al. Spanish LupusPRO: cross-cultural validation study for lupus. Lupus. 2013;22(5):431–6.PubMedCrossRef

47.

Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, et al. The patient reported outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort. Lupus. 2011;12:1285–92.CrossRef

48.

Carr FN, Nicassio PM, Ishimori ML, Moldovan I, Katsaros E, Torralba K, et al. Depression predicts self-reported disease activity in systemic lupus erythematosus. Lupus. 2011;20(1):80–4.PubMedCrossRef

49.

Choi ST, Kang JI, Park IH, Lee YW, Song JS, Park YB, et al. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol. 2012;30(5):665–72.PubMed

50.

Kulczycka L, Sysa-Jedrzejowska A, Robak E. Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin Rheumatol. 2010;29(9):991–7.PubMedCrossRef

51.

Daleboudt GM, Broadbent E, Berger SP, Kaptein AA. Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis. Lupus. 2011;3:290–8.CrossRef

52.

Appenzeller S, Clarke AE, Panopalis P, Joseph L, St Pierre Y, Li T. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol. 2009;36(5):947–52.PubMedCrossRef

53.

Hyphantis T, Palieraki K, Voulgari PV, Tsifetaki N, Drosos AA. Coping with health-stressors and defence styles associated with health-related quality of life in patients with systemic lupus erythematosus. Lupus. 2011;9:893–903.CrossRef

54.

McElhone K, Castelino M, Abbott J, Bruce IN, Ahmad Y, Shelmerdine J, et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(11):2273–9.PubMedCrossRef

55.

Jolly M, Pickard SA, Mikolaitis RA, Rodby RA, Sequeira W, Block JA. LupusQoL-US benchmarks for US patients with systemic lupus erythematosus. J Rheumatol. 2010;37(9):1828–33.PubMedCrossRef

56.

Jolly M, Kazmi N, Mikolaitis RA, Sequeira W, JA B. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. 2012.

57.

Navarrete-Navarrete N, Peralta-Ramírez MI, Sabio-Sánchez JM, et al. Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom. 2010;79(2):107–15.PubMedCrossRef

58.

Abrahao MI, Montenegro-Rodrigues R, Marangoni RG. et al. Impact of physical activity program in systemic Lupus Erythematosus. Arthritis & Rheum. 2009;60(10 S):1123-.

59.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30.PubMedCrossRef

60.

Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis. 2010;69(6):1144–7.PubMedCrossRef

61.

Griffiths B, Emery P, Ryan V, Isenberg D, Akil M, Thompson R, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology. 2010;49(4):723–32. Erratum appears in Rheumatology (Oxford). 2011 Mar;50(3):634.PubMedCrossRef

62.

Jolly M, Sandler DS, Sequeira W, Block JA. Hydroxy-Chloroquine Use and Disease Specific Health Related Quality of Life in Systemic Lupus Erythematosus. Arthritis Rheum. 2010;60(10s):S108.

63.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33.PubMedCrossRef

64.

van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9.PubMedCrossRef

65.

Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singap. 2007;36(2):115–22 [Review] [56 refs].PubMed

66.

Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999;58(6):379–81.PubMedCrossRef

67.

Torrente-Segarra V, Carbonell-Abello J, Castro-Oreiro S, Manresa Dominguez JM. Association between fibromyalgia and psychiatric disorders in systemic lupus erythematosus. Clin Exp Rheumatol. 2010;28(6 Suppl 63):S22–6.PubMed

68.

Hanly JG, Su L, Omisade A, Farewell VT, Fisk JD. Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2012;39(7):1371–7.PubMedCrossRef

69.

Peretti CS, Peretti CR, Kozora E, Papathanassiou D, Chouinard VA, Chouinard G. Cognitive impairment in systemic lupus erythematosus women with elevated autoantibodies and normal single photon emission computerized tomography. Psychother Psychosom. 2012;81(5):276–85.PubMedCrossRef

70.

Julian LJ, Tonner C, Yelin E, Yazdany J, Trupin L, Criswell LA, et al. Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus. Arthritis Care Res. 2011;63(4):542–9.CrossRef

71.

Jolly M, Mikolaitis RA, Shakoor N, Fogg LF, Block JA. Education, zip code-based annualized household income, and health outcomes in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(6):1150–7.PubMedCrossRef

72.

Dua AB, Aggarwal R, Mikolaitis RA, Sequeira W, Block JA, Jolly M. Rheumatologists’ quality of care for lupus: comparison study between a university and county hospital. Arthritis Care Res. 2012;64(8):1261–4.

73.

Bennett JK, Fuertes JN, Keitel M, Phillips R. The role of patient attachment and working alliance on patient adherence, satisfaction, and health-related quality of life in lupus treatment. Patient Educ Couns. 2011;85(1):53–9.PubMedCrossRef

74.

Zuluaga MC, Guallar-Castillon P, Lopez-Garcia E, Banegas JR, Conde-Herrera M, Olcoz-Chiva M, et al. Generic and disease-specific quality of life as a predictor of long-term mortality in heart failure. Eur J Heart Fail. 2010;12(12):1372–8.PubMedCrossRef

75.

Kanwal F, Gralnek IM, Hays RD, Zeringue A, Durazo F, Han SB, et al. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol. 2009;7(7):793–9.PubMedCrossRef

76.

Issa SM, Hoeks SE, Scholte op Reimer WJ, Van Gestel YR, Lenzen MJ, Verhagen HJ, et al. Health-related quality of life predicts long-term survival in patients with peripheral artery disease. Vasc Med. 2010;15(3):163–9.PubMedCrossRef

77.

Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol. 2012;39(1):54–9.PubMedCrossRef

78.

Fernandez M, Alarcon GS, McGwin Jr G, Sanchez ML, Apte M, Vila LM, et al. Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis Rheum. 2007;57(6):986–92.PubMedCrossRef

79.

Lupus Applications for Android. Internet [Internet]. 2013 9/13/13 AD. Available from: http://blog.laptopmag.com/best-lupus-apps?slide=1.

80.

Healthy Tweeting. Internet [Internet]. 2013; Last accessed 09/13/2013. Available from: http://www.healthytweeting.com/.

81.

USinLUPUS. Lupus Impact Tracker. Last lvisited 12/11/12 [Internet]. 2012. Available from: http://www.usinlupus.com/content/dam/usinlupus/.

82.

Touma Z, Gladman DD, Ibanez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic Lupus Erythematosus? J Rheumatol. 2011;38:1898–905.PubMedCrossRef

83.

Ware JE. The SF-36 Health Survey. In: B S, editor. Quality of life and pharmacoeconomics in clinical trials. Second ed. Philadelphia: Lippincott-Raven; 1996. p. 337–45.

84.

Brazier JE, Tsuchiya A, Roberts J, J B. A comparison of the EQ-5D and the SF-6D across seven patient groups. Health Economics. 2004;13:873–84.

85.

Group E. EuroQol: a new facility for the measurement of health-related quality of life. Health Pol. 1990;16:199–208.CrossRef

Titel: Top 10 Recent Developments in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
verfasst von: Anisha B. Dua
Zahi Touma
Sergio Toloza
Meenakshi Jolly
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 12/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-013-0380-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

Animal Models of Scleroderma: Current State and Recent Development

Yoga in Rheumatic Diseases

Osteopenia: Debates and Dilemmas

The Future of Osteoarthritis Therapeutics: Emerging Biological Therapy

Perioperative Infection in the Patient with Rheumatic Disease

Scleroderma-Related Lung Disease: Are Adipokines Involved Pathogenically?